Treatment for Trichotillomania in Adult Women
For an adult woman with trichotillomania, initiate habit reversal training (HRT) as first-line treatment, and if behavioral therapy is insufficient or not feasible, add N-acetylcysteine as pharmacotherapy due to its favorable benefit-to-risk profile.
Treatment Algorithm
First-Line: Behavioral Intervention
Habit reversal training should be the initial treatment approach 1, 2. HRT has the most robust empirical support for trichotillomania and works by:
- Awareness training: Teaching the patient to recognize pulling urges and the specific situations/emotions that trigger pulling
- Competing response procedures: Developing alternative behaviors incompatible with hair pulling (e.g., clenching fists, sitting on hands)
- Stimulus control: Modifying the environment to reduce pulling opportunities
HRT typically involves 8-10 sessions and demonstrates consistent therapeutic benefit across studies 3, 1. Acceptance and Commitment Therapy (ACT) has also shown efficacy comparable to HRT, with significant reductions in symptom severity and daily hairs pulled 3.
Stepped Care Approach
If the patient cannot access in-person therapy immediately, consider web-based self-help as an initial step 4. While effect sizes are modest (d = 0.21), this approach is highly acceptable, maintains motivation, and 76% of patients subsequently engage in formal HRT when needed 4.
Pharmacotherapy Options
When to Add Medication
Consider pharmacotherapy when:
- Behavioral therapy alone is insufficient
- The patient cannot access or tolerate behavioral interventions
- Severity is significant with substantial functional impairment
- Psychiatric comorbidities are present
First-Line Pharmacotherapy: N-Acetylcysteine
N-acetylcysteine is the preferred initial pharmacological agent due to significant benefits with minimal side effects 5, 6. This glutamate-modulating agent addresses the neurobiological underpinnings of repetitive behaviors without the adverse effect burden of other medications.
Alternative Pharmacological Options
If N-acetylcysteine is ineffective, consider 6, 2:
Clomipramine: Has preliminary evidence for efficacy but carries higher risk of side effects (anticholinergic effects, cardiac concerns, seizure risk)
SSRIs: Evidence is mixed and insufficient to support as first-line, though may be beneficial when comorbid depression/anxiety is present
Olanzapine: Preliminary evidence suggests potential benefit, but metabolic side effects limit use
Real-World Prescribing Patterns vs. Evidence
Important caveat: Current real-world practice shows concerning patterns with benzodiazepines being most commonly prescribed (37% in US, 21% in Europe), despite lack of evidence supporting their use 7. This represents a significant gap between evidence-based recommendations and actual practice. Avoid benzodiazepines as they do not address the core pathology and carry dependence risks.
Combined Treatment Strategy
The most effective approach combines behavioral therapy with pharmacotherapy when needed 2. Augmenting behavioral interventions with medication can enhance outcomes, particularly in treatment-resistant cases or when psychiatric comorbidities complicate the clinical picture.
Critical Clinical Considerations
Therapeutic Relationship
Maintain a nonjudgmental, empathic, and inviting attitude 5. Many patients deny the behavior or feel shame, which can impede treatment engagement.
Addressing Perfectionism
Recent evidence suggests perfectionism plays a central role in maintaining hair-pulling behavior 8. The pulling serves to prevent confirmation of self-critical cognitions. Explicitly address perfectionistic beliefs in therapy, as this may be a key maintaining factor.
Monitoring and Duration
- Assess treatment response at 8-10 weeks for behavioral interventions
- For pharmacotherapy, allow adequate trial duration (similar to OCD treatment paradigms of 8-12 weeks)
- Relapse is common, particularly in adults 2, necessitating ongoing monitoring and booster sessions
Comorbidity Management
Trichotillomania has high rates of psychiatric comorbidity 6. Screen for and address co-occurring conditions (depression, anxiety, OCD) as these may influence treatment selection and outcomes.
What Doesn't Work
- Punishment or negative feedback: Completely ineffective and counterproductive
- Benzodiazepines as monotherapy: No evidence base despite common real-world use 7
- Waiting for spontaneous remission: The condition is chronic with fluctuating course requiring active intervention